Tags

Type your tag names separated by a space and hit enter

Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma.
Ann Surg Oncol 2009; 16(11):2968-77AS

Abstract

BACKGROUND

Blacks have a higher incidence of pancreatic adenocarcinoma and worse outcomes compared to whites. Identifying barriers in pancreatic cancer care may explain survival differences and provide areas for intervention.

METHODS

Pancreatic adenocarcinoma patients were identified in the Surveillance, Epidemiology, and End Results Registry (1991-2002). Treatment and outcome data were obtained from the linked Surveillance, Epidemiology, and End Results Registry-Medicare databases. Logistic regression was used to assess race as a predictor of specialist consultation/receipt of therapy. Kaplan-Meier survival curves were compared. Cox proportional hazard analyses were performed to estimate survival after adjustment for patient and treatment characteristics.

RESULTS

A total of 13,230 white patients (90%) and 1478 black patients (10%) were identified. Clinical/pathologic factors were compared by race. When we compared whites and blacks by univariate analyses, blacks had lower rates of specialist consultation (P<.01), chemotherapy (P<.01), and resection (P<.01). On multivariate analyses predicting consultation with a cancer specialist, black race negatively predicted consultation with a medical oncologist (adjusted odds ratio [AOR] .74, P<.01), radiation oncologist (AOR .75, P<.01), and surgeon (AOR .71, P<.01). For predicting receipt of therapy after consultation, blacks were less likely to undergo chemotherapy (AOR .59, P<.01) and resection (AOR .79, P=.05). Blacks had worse overall survival on Kaplan-Meier survival curves (log rank, P<.0001). On Cox proportional hazard modeling evaluating survival, black race was no longer independently associated with worse survival after adjustment for resection and adjuvant therapy (hazard ratio, 1.08; 95% confidence interval, .99-1.19).

CONCLUSIONS

Racial disparities exist in pancreatic cancer specialist consultation and subsequent therapy use. Because receipt of care is fundamental to reducing outcome discrepancies, these barriers serve as discrete intervention points to ensure all locoregional pancreatic adenocarcinoma patients receive appropriate specialist referral and subsequent therapy.

Authors+Show Affiliations

Department of Surgery, Surgical Outcomes Analysis and Research, University of Massachusetts Medical School, Worcester, MA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19669839

Citation

Murphy, Melissa M., et al. "Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma." Annals of Surgical Oncology, vol. 16, no. 11, 2009, pp. 2968-77.
Murphy MM, Simons JP, Ng SC, et al. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(11):2968-77.
Murphy, M. M., Simons, J. P., Ng, S. C., McDade, T. P., Smith, J. K., Shah, S. A., ... Tseng, J. F. (2009). Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Annals of Surgical Oncology, 16(11), pp. 2968-77. doi:10.1245/s10434-009-0656-5.
Murphy MM, et al. Racial Differences in Cancer Specialist Consultation, Treatment, and Outcomes for Locoregional Pancreatic Adenocarcinoma. Ann Surg Oncol. 2009;16(11):2968-77. PubMed PMID: 19669839.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. AU - Murphy,Melissa M, AU - Simons,Jessica P, AU - Ng,Sing Chau, AU - McDade,Theodore P, AU - Smith,Jillian K, AU - Shah,Shimul A, AU - Zhou,Zheng, AU - Earle,Craig C, AU - Tseng,Jennifer F, Y1 - 2009/08/11/ PY - 2009/05/15/received PY - 2009/07/03/accepted PY - 2009/8/12/entrez PY - 2009/8/12/pubmed PY - 2010/1/20/medline SP - 2968 EP - 77 JF - Annals of surgical oncology JO - Ann. Surg. Oncol. VL - 16 IS - 11 N2 - BACKGROUND: Blacks have a higher incidence of pancreatic adenocarcinoma and worse outcomes compared to whites. Identifying barriers in pancreatic cancer care may explain survival differences and provide areas for intervention. METHODS: Pancreatic adenocarcinoma patients were identified in the Surveillance, Epidemiology, and End Results Registry (1991-2002). Treatment and outcome data were obtained from the linked Surveillance, Epidemiology, and End Results Registry-Medicare databases. Logistic regression was used to assess race as a predictor of specialist consultation/receipt of therapy. Kaplan-Meier survival curves were compared. Cox proportional hazard analyses were performed to estimate survival after adjustment for patient and treatment characteristics. RESULTS: A total of 13,230 white patients (90%) and 1478 black patients (10%) were identified. Clinical/pathologic factors were compared by race. When we compared whites and blacks by univariate analyses, blacks had lower rates of specialist consultation (P<.01), chemotherapy (P<.01), and resection (P<.01). On multivariate analyses predicting consultation with a cancer specialist, black race negatively predicted consultation with a medical oncologist (adjusted odds ratio [AOR] .74, P<.01), radiation oncologist (AOR .75, P<.01), and surgeon (AOR .71, P<.01). For predicting receipt of therapy after consultation, blacks were less likely to undergo chemotherapy (AOR .59, P<.01) and resection (AOR .79, P=.05). Blacks had worse overall survival on Kaplan-Meier survival curves (log rank, P<.0001). On Cox proportional hazard modeling evaluating survival, black race was no longer independently associated with worse survival after adjustment for resection and adjuvant therapy (hazard ratio, 1.08; 95% confidence interval, .99-1.19). CONCLUSIONS: Racial disparities exist in pancreatic cancer specialist consultation and subsequent therapy use. Because receipt of care is fundamental to reducing outcome discrepancies, these barriers serve as discrete intervention points to ensure all locoregional pancreatic adenocarcinoma patients receive appropriate specialist referral and subsequent therapy. SN - 1534-4681 UR - https://www.unboundmedicine.com/medline/citation/19669839/Racial_differences_in_cancer_specialist_consultation_treatment_and_outcomes_for_locoregional_pancreatic_adenocarcinoma_ L2 - https://dx.doi.org/10.1245/s10434-009-0656-5 DB - PRIME DP - Unbound Medicine ER -